How much revenue does Concord Drugs make?

Concord Drugs reported 452.45 million INR in revenue for fiscal year 2025, up 0.7% from 449.25 million INR in fiscal year 2024. In Q3 2026 revenue was 169.66 million INR.

What companies are similar to Concord Drugs?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Auro Laboratories Limited (AUROLAB.BO), Gujarat Inject (Kerala) Ltd (GUJINJEC.BO), Parnax Lab Limited (PARNAXLAB.BO), Mercury Laboratories Limited (MERCURYLAB.BO).

Concord Drugs Limited (CONCORD.BO) Stock

About Concord Drugs Limited

Concord Drugs Limited engages in the manufacture and sale of pharmaceutical formulations in India. It offers tissue bio-adhesive products; ready-to-fill pellets and multiple unit pellets system; other drugs in the form of tablets, capsules, injectables such as small volume parenterals, dry powders, syrups and suspension, and dry syrups; and hand sanitizers. Concord Drugs Limited was incorporated i...

At a glance

Concord Drugs reported revenue of 452.45 million INR for fiscal year 2025, up 0.7% from fiscal year 2024, and net income of 3.36 million INR. In Q3 2026 (the quarter ended December 31, 2025) revenue was 169.66 million INR, up 57.1% from a year before.

Figures from company filings; latest fiscal year ended March 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.